Differential platelet levels affect response to taxane-based therapy in ovarian cancer

• Published in: Clinical cancer research Vol. 21; no. 3; pp. 602 - 610
• Main Authors: Bottsford-Miller, Justin, Choi, Hyun-Jin, Dalton, Heather J, Stone, Rebecca L, Cho, Min Soon, Haemmerle, Monika, Nick, Alpa M, Pradeep, Sunila, Zand, Behrouz, Previs, Rebecca A, Pecot, Chad V, Crane, Erin King, Hu, Wei, Lutgendorf, Susan K, Afshar-Kharghan, Vahid, Sood, Anil K
• Format: Journal Article
• Language: English
• Published: United States 01.02.2015
• Subjects: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Bridged-Ring Compounds - administration & dosage; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms - blood; Ovarian Neoplasms - complications; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Platelet Count; Retrospective Studies; Taxoids - administration & dosage; Thrombosis - etiology; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

We hypothesized that platelet levels during therapy could serve as a biomarker for response to therapy and that manipulation of platelet levels could impact responsiveness to chemotherapy. The medical records of patients with recurrent or progressive ovarian cancer were retrospectively queried for c...